Our Focus

The Colorado Chapter of the National Bleeding Disorders Foundation (NBDF Colorado) is responsible for addressing the challenges bleeding disorder patients and their families face through education, advocacy, and empowerment.

El Capítulo de Colorado de la Fundación Nacional de Trastornos Hemorrágicos (NBDF Colorado) es responsable de abordar los desafíos que enfrentan los pacientes con trastornos hemorrágicos y sus familias a través de la educación, la defensa y el empoderamiento. Visite nuestra página en español aquí.

News Articles

For Immediate Release 
Kyla Clark 
National Bleeding Disorders Foundation 
kclark@hemophilia.org%C2%A0" title="Email for Kyla Clark">kclark@bleeding.org 


NBDF Unveils THRIVE Campaign: Empowering Individuals with Bleeding Disorders through 6 Essential Steps


Pfizer recently provided new clinical trial updates for their investigational therapy marstacimab. The data was presented last month at the 2024 annual meeting of the European Hematology Association (EHA) in Madrid. Marstacimab is a laboratory-engineered monoclonal antibody developed to treat hemophilia A and B patients, with or without inhibitors.


The National Bleeding Disorders Foundation (NBDF) is excited to announce a new accredited educational opportunity for healthcare providers. This live/virtual program will focus on optimizing non-factor replacement therapy for hemophilia patients. 



Resource Links

13199 E Montview Blvd
STE 200
Aurora, CO 80045

© National Bleeding Disorders Foundation 2024

Crafted by Firespring